Classifica tra le azioni
#31262
Noxopharm Limited is an Australian drug development company with an... Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvant therapy designed to augment the effectiveness of chemotherapy and radiotherapy in treating late-stage cancers. Beyond Veyonda, the company's robust development pipeline encompasses several key programs: The DARRT program, currently in Phase 1b/2a clinical trials, is addressing metastatic castration-resistant prostate cancer and other solid tumors. The LuPIN program explores a combined therapy of Veyonda and 177Lu-PSMA-617 for advanced prostate cancer. The IONIC program combines Veyonda with Bristol Myers Squibb's checkpoint inhibitor, Opdivo, targeting various solid tumor types. Its Chemotherapy Enhancement Program (CEP) integrates Veyonda with carboplatin for patients suffering from refractory solid tumors in areas such as the breast, head and neck, lung, prostate, and ovaries. Furthermore, the NOXCOVID Program is conducting a dose escalation and expansion study of NOX66 for the treatment of COVID-19 infection. The company is also investigating potential treatments for pancreatic cancer and glioblastoma. Noxopharm collaborates with the Hudson Institute of Medical Research and The Australian National University on the research and development of therapeutic drugs for inflammatory disorders. Incorporated in 2015, the company's operations are based in Chatswood, Australia.
Prezzo delle azioni
$0.04443294
Capitalizzazione di mercato
$13.65M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
-32.53%
Scambia Noxopharm Limited (NOX)
Numero di azioni in circolazione per Noxopharm Limited (NOX)
Numero di azioni in circolazione al June 2026: 290.49M
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Noxopharm Limited, il numero attuale di azioni in circolazione è 290.49M. Alla fine del June 2024, la società aveva 292.26M azioni in circolazione. Il numero di azioni in circolazione è solitamente influenzato da split azionari e riacquisti.
Storico delle azioni in circolazione di Noxopharm Limited (NOX) dal 2016 al 2026
Azioni in circolazione alla fine di ogni anno
| Anno |
Azioni in circolazione |
Cambia |
|
2026 (TTM) |
290.49M |
-0.67%
|
|
2025 |
292.47M |
0.07%
|
|
2024 |
292.26M |
0.01%
|
|
2023 |
292.24M |
0.35%
|
|
2022 |
291.22M |
10.37%
|
|
2021 |
263.85M |
90.70%
|
|
2020 |
138.36M |
0.15%
|
|
2019 |
138.15M |
16.06%
|
|
2018 |
119.03M |
35.93%
|
|
2017 |
87.57M |
160.94%
|
|
2016 |
33.56M |
0.00%
|
Azioni in circolazione per aziende simili o concorrenti
| Azienda |
Azioni in circolazione |
Differenza |
Il paese |
|
|
253.90M |
-12.60%
|
US
|
|
|
396.00M |
36.32%
|
US
|
|
|
478.91M |
64.86%
|
AU
|
|
|
62.19M |
-78.59%
|
NL
|
|
|
- |
-
|
CH
|
